JP2017519729A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519729A5
JP2017519729A5 JP2016567425A JP2016567425A JP2017519729A5 JP 2017519729 A5 JP2017519729 A5 JP 2017519729A5 JP 2016567425 A JP2016567425 A JP 2016567425A JP 2016567425 A JP2016567425 A JP 2016567425A JP 2017519729 A5 JP2017519729 A5 JP 2017519729A5
Authority
JP
Japan
Prior art keywords
carboxamide
oxabicyclo
heptane
pyridin
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567425A
Other languages
English (en)
Japanese (ja)
Other versions
JP6479051B2 (ja
JP2017519729A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030303 external-priority patent/WO2015175487A1/en
Publication of JP2017519729A publication Critical patent/JP2017519729A/ja
Publication of JP2017519729A5 publication Critical patent/JP2017519729A5/ja
Application granted granted Critical
Publication of JP6479051B2 publication Critical patent/JP6479051B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567425A 2014-05-13 2015-05-12 軟骨形成を誘導するための化合物および組成物 Active JP6479051B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992815P 2014-05-13 2014-05-13
US61/992,815 2014-05-13
PCT/US2015/030303 WO2015175487A1 (en) 2014-05-13 2015-05-12 Compounds and compositions for inducing chondrogenesis

Publications (3)

Publication Number Publication Date
JP2017519729A JP2017519729A (ja) 2017-07-20
JP2017519729A5 true JP2017519729A5 (https=) 2018-06-07
JP6479051B2 JP6479051B2 (ja) 2019-03-06

Family

ID=53284520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567425A Active JP6479051B2 (ja) 2014-05-13 2015-05-12 軟骨形成を誘導するための化合物および組成物

Country Status (39)

Country Link
US (6) US9688689B2 (https=)
EP (2) EP4474384A1 (https=)
JP (1) JP6479051B2 (https=)
KR (1) KR102375396B1 (https=)
CN (1) CN106459076B (https=)
AP (1) AP2016009502A0 (https=)
AR (1) AR100418A1 (https=)
AU (1) AU2015259403B2 (https=)
BR (1) BR112016025659B1 (https=)
CA (1) CA2947031C (https=)
CL (1) CL2016002838A1 (https=)
CR (1) CR20160528A (https=)
CU (1) CU24392B1 (https=)
DK (1) DK3143026T3 (https=)
EA (1) EA031609B1 (https=)
ES (1) ES2987439T3 (https=)
FI (1) FI3143026T3 (https=)
HR (1) HRP20241236T1 (https=)
HU (1) HUE067954T2 (https=)
IL (1) IL248400B (https=)
JO (1) JO3563B1 (https=)
LT (1) LT3143026T (https=)
MA (1) MA39972B1 (https=)
MX (1) MX377796B (https=)
MY (1) MY186570A (https=)
NZ (1) NZ725044A (https=)
PE (1) PE20161432A1 (https=)
PH (1) PH12016502005B1 (https=)
PL (1) PL3143026T3 (https=)
PT (1) PT3143026T (https=)
RS (1) RS66122B1 (https=)
SG (1) SG11201608823RA (https=)
SI (1) SI3143026T1 (https=)
SV (1) SV2016005316A (https=)
TN (1) TN2016000441A1 (https=)
TW (1) TWI662039B (https=)
UY (1) UY36118A (https=)
WO (1) WO2015175487A1 (https=)
ZA (1) ZA201606929B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1224172A1 (zh) 2013-03-15 2017-08-18 加州生物医学研究所 用於诱导软骨形成的化合物和方法
DK3143026T3 (da) * 2014-05-13 2024-09-30 Novartis Ag Forbindelser og sammensætninger til induktion af chondrogenese
KR20240045351A (ko) * 2016-11-14 2024-04-05 노파르티스 아게 연골 손상 및 관절염 치료 방법 및 조성물
EP3615021A4 (en) * 2017-04-24 2020-12-30 The Scripps Research Institute CHONDROGENESIS INDUCTION METHODS
UY37759A (es) 2017-06-09 2019-01-31 Novartis Ag Compuestos y composiciones para inducir condrogénesis
EP3706710B1 (en) * 2017-11-10 2024-04-10 Novartis AG Extended release formulations for intra-articular applications
KR20210038877A (ko) 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
EP3891155B1 (en) * 2018-12-06 2023-08-30 Novartis AG 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
CN113015735B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物
CN111601789A (zh) * 2018-12-20 2020-08-28 江苏凯迪恩医药科技有限公司 一种含氮杂环化合物、其制备方法及应用
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
RU2733472C1 (ru) * 2020-02-26 2020-10-01 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) N-Ацилгидразон фенхона с фрагментом эпоксиизоиндола, используемый в качестве ингибитора репродукции вируса Хантаан
CN114763347B (zh) * 2021-01-15 2024-06-21 华东师范大学 一类用于诱导间充质干细胞向软骨分化的化合物及其应用
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2205274B1 (https=) 1972-11-02 1976-10-01 Sumitomo Chemical Co
US3925554A (en) 1972-11-30 1975-12-09 Sumitomo Chemical Co Certain 3,5-dichlorophenyl compound used as a plant fungicide
US4687865A (en) 1986-06-04 1987-08-18 E. R. Squibb & Sons, Inc. Process for preparing 7-oxabicycloheptane amino-alcohol intermediates useful in making thromboxane A2 receptor antagonists
US4707494A (en) * 1986-08-26 1987-11-17 E. R. Squibb & Sons, Inc. 7-oxabicyclo(2.2.1)heptane compounds useful in the treatment of inflammation
JP2984077B2 (ja) 1990-04-19 1999-11-29 塩野義製薬株式会社 スルホニルアミノ置換ビシクロ環系ヒドロキサム酸誘導体
US5126370A (en) 1990-12-24 1992-06-30 E. R. Squibb & Sons, Inc. Anti-thrombotic heterocyclic amido prostaglandin analogs
JPH04275182A (ja) 1991-03-01 1992-09-30 Sankyo Kagaku Kk 感熱転写記録用色素
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5399725A (en) 1993-05-27 1995-03-21 Bristol-Myers Squibb Co. 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same
AU701227B2 (en) 1993-09-10 1999-01-21 Cytomed, Inc Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US6017953A (en) 1993-12-28 2000-01-25 Allergan Sales, Inc. Thromboxane ligands
US5416106A (en) 1993-12-28 1995-05-16 Allergan, Inc. 7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof
FR2718136B1 (fr) 1994-03-29 1996-06-21 Sanofi Sa Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
EP0912170A4 (en) 1996-05-02 2003-04-09 Merck & Co Inc HIV PROTEASE INHIBITORS FOR TREATING AIDS
JP3338064B2 (ja) 1997-01-06 2002-10-28 ファイザー・インク 環状スルホン誘導体
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
GB9908021D0 (en) * 1999-04-08 1999-06-02 Lilly Co Eli Pharmaceutical compounds
WO2000066577A2 (en) 1999-04-29 2000-11-09 Allergan Sales, Inc. Brigded cycloalkanes as thromboxane ligands without blood clotting effects
WO2001047510A2 (en) 1999-12-29 2001-07-05 Glaxo Group Limited Methods and compositions related to modulators of annexin and cartilage homeostasis
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
CN1213050C (zh) * 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物,其制备方法和作为农药的用途
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
JP4497815B2 (ja) 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な複素環式アミド誘導体およびドーパミンd3受容体リガンドとしてのその使用
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
WO2003072578A1 (en) 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CA2518193A1 (en) 2003-03-04 2004-09-16 Pfizer Products Inc. Use of ep2 selective receptor agonists in medical treatment
EP2422814A1 (en) 2003-07-25 2012-02-29 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
JP2005097195A (ja) 2003-09-25 2005-04-14 Institute Of Physical & Chemical Research 医薬組成物
EP1680464A1 (en) 2003-11-07 2006-07-19 Milliken & Company Concentrates of saturated bicyclic dicarboxylate salts as polymer nucleation additives and methods of nucleating thermoplastics
EP2708541B1 (en) 2003-11-13 2015-01-28 Isis Pharmaceuticals, Inc. 5,6-dihydroxy-isoindole derivatives as linkers for oligomer solid phase synthesis
US20050203086A1 (en) 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
EP1792622A1 (en) * 2005-11-11 2007-06-06 GPC Biotech AG Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
US7795370B2 (en) 2005-11-15 2010-09-14 Mitsubishi Chemical Corporation Tetracarboxylic acid compound, polyimide thereof, and production method thereof
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US7566797B2 (en) 2006-03-03 2009-07-28 Milliken & Company Metal carboxylate salt nucleating or clarifying agent compounds and related polymer compositions and methods
CA2676422C (en) 2007-02-06 2018-10-16 Lixte Biotechnology Holdings, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
JP4275182B2 (ja) 2007-11-02 2009-06-10 シャープ株式会社 熱交換器
EP2309853A4 (en) 2008-08-01 2012-04-25 Lixte Biotechnology Inc METHOD FOR CELL MITITULATING BY INHIBITION OF SERIN / THREONINE PHOSPHATASE
CA2730148C (en) 2008-08-01 2018-04-03 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
JP2011530511A (ja) * 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
WO2010099573A1 (en) 2009-03-03 2010-09-10 Deakin University Dioxolane norbornane / norbornene compounds suitable as antimicrobial agents to treat bacterial infections
AU2010232556A1 (en) 2009-04-02 2011-11-03 Allergan, Inc. Prostaglandin E receptor antagonists
AU2010250789B2 (en) 2009-05-18 2015-05-14 Actelion Pharmaceuticals Ltd Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists
JP5602850B2 (ja) 2009-07-14 2014-10-08 ザ スクリプス リサーチ インスティテュート 間葉幹細胞分化
CN101628951B (zh) * 2009-08-12 2011-06-22 中国石油天然气股份有限公司 烯烃聚合用固体催化组分及其催化剂
JP5478161B2 (ja) 2009-09-03 2014-04-23 株式会社クラレ アクリル酸エステル誘導体およびアルコール誘導体並びにそれらの製造方法
US8551955B2 (en) 2009-10-28 2013-10-08 Joyant Pharmaceuticals, Inc. Dimeric Smac mimetics
US8754059B2 (en) 2010-02-16 2014-06-17 University Of Miami Use of miR-30e to treat vascular lesions
EP2585054A1 (en) 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
KR101905927B1 (ko) 2010-11-17 2018-10-08 이도르시아 파마슈티컬스 리미티드 가교된 스피로[2.4]헵탄 에스테르 유도체
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US20140235649A1 (en) * 2011-05-24 2014-08-21 Lixte Biotechnology, Inc. Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
CA2871334A1 (en) 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
JP6262225B2 (ja) 2012-06-29 2018-01-17 リクスト・バイオテクノロジー,インコーポレイテッド オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
CA2877167A1 (en) 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
EP2983661B1 (en) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
WO2015007830A1 (en) 2013-07-18 2015-01-22 Actelion Pharmaceuticals Ltd Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
DK3143026T3 (da) * 2014-05-13 2024-09-30 Novartis Ag Forbindelser og sammensætninger til induktion af chondrogenese

Similar Documents

Publication Publication Date Title
JP2017519729A5 (https=)
HRP20241236T1 (hr) Spojevi i pripravci za induciranje hondrogeneze
US8685993B2 (en) Bi-heteroaryl compounds as Vps34 inhibitors
CA2984259A1 (en) Combinations of inhibitors of irak4 with inhibitors of btk
JP6175673B2 (ja) Ttx−s遮断薬としてのアミド誘導体
SA520411465B1 (ar) مركبات فعّالة علاجياً وطرق استخدامها
EP2739616A1 (en) Pyridin-2(1h)-one derivatives as jak inhibitors
EP3661560A1 (en) Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors
WO2005117883A1 (en) Modulators of muscarinic receptors
BRPI0720270A2 (pt) Compostos basedos em 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina e processos de usos dos mesmos
JP2010508338A5 (https=)
AR069206A1 (es) Derivados de 2-pirazinona, proceso para preparalos, composiciones farmaceuticas que los comprenden, proceso de preparacion de las mismas y usos en el tratamiento de trastornos osteoarticularesy del aparato respiratorio, entre otros.
RU2010116352A (ru) Производные 1,1,1-трифтор-2-гидрокси-3-фенилпропана
CA2845578A1 (en) Pyrimidine pde10 inhibitors
JP2019532911A (ja) Nav1.7およびNav1.8遮断薬としてのアミド誘導体
TW201546070A (zh) 4-氮雜吲哚衍生物
IL205501A (en) Preparation of preparations for the treatment of arthritis
EP3849664A1 (en) Phenoxy-pyridyl-pyrimidine compounds and methods of use
EP3585365A1 (en) Combination of atr kinase inhibitors with parp inhibitors
WO2020065048A1 (en) Novel compounds as nadph oxidase inhibitors
JP2021521178A (ja) Pi3キナーゼおよびオートファジー経路の調節因子としての三置換アリールおよびヘテロアリール誘導体
JP2023550902A5 (https=)
JP2026504481A (ja) ジアシルグリセロールキナーゼ(dgk)阻害剤の組合せ
TW202602875A (zh) Stat6降解劑
EA045967B1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими